骨疏康对绝经后骨质疏松症的影响：系统评价与Meta分析方案
Effects of Gushukang for postmenopausal osteoporosis: A protocol for systematic review and meta-analysis.
作者信息
Wang Guangwei, Huo Liwei, Chen Guocai, He Huayong
机构信息
Guangzhou Orthopedic Hospital.
The Fifth Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
出版信息
Medicine (Baltimore). 2020 Jul 2;99(27):e20908. doi: 10.1097/MD.0000000000020908.
BACKGROUND
Postmenopausal osteoporosis (PMO) is one of the most common systemic bone diseases with a high risk of fracture. Traditional herbal formula Gushukang (GSK) has been used to treat PMO. However, there is no systematic review related to GSK for PMO. The object of this work is to evaluate the efficacy and safety of GSK in the management of PMO.
METHODS
We will search the PubMed, Embase, MEDLINE, Cochrane Library Central Register of Controlled Trials, China national knowledge infrastructure database (CNKI), Wan fang database, Chongqing VIP information, and SinoMed from their inception to May 2020. All randomized controlled trials (RCTs) of GSK for the treatment of PMO will be included. The improvement of vertebral fracture and bone mineral density (BMD) will be accepted as the primary outcomes. The meta-analyses will be performed by using the RevMan 5.3.
RESULTS
This study will provide a high-quality comprehensive evaluation of the efficacy and safety of GSK for treating patients with PMO.
CONCLUSION
The conclusion of our systematic review will provide evidence to judge whether GSK is an effective intervention for patients with PMO.
TRIAL REGISTRATION NUMBER
10.17605/OSF.IO/MKN3F.
背景
绝经后骨质疏松症（PMO）是最常见的全身性骨病之一，骨折风险高。传统中药方剂骨舒康（GSK）已用于治疗PMO。然而，尚无关于GSK治疗PMO的系统评价。本研究的目的是评估GSK治疗PMO的有效性和安全性。
方法
我们将检索PubMed、Embase、MEDLINE、Cochrane图书馆临床试验中央注册库、中国国家知识基础设施数据库（CNKI）、万方数据库、重庆维普资讯和中国生物医学文献数据库，检索时间从建库至2020年5月。纳入所有GSK治疗PMO的随机对照试验（RCT）。将椎体骨折改善情况和骨密度（BMD）作为主要结局指标。采用RevMan 5.3软件进行荟萃分析。
结果
本研究将对GSK治疗PMO患者的有效性和安全性进行高质量的综合评价。
结论
我们系统评价的结论将为判断GSK是否为PMO患者的有效干预措施提供证据。
试验注册号
10.17605/OSF.IO/MKN3F。
Zotero 插件